Decreased expression of mGluR5 within the dorsolateral prefrontal cortex in autism and increased microglial number in mGluR5 knockout mice: Pathophysiological and neurobehavioral implications
Introduction
To date, the aetiology of autism spectrum disorder (ASD) remains poorly understood with diagnosis relying solely on clinical interview. Evidence linking the metabotropic glutamate receptor (mGluR5) to ASD pathogenesis has come from studies demonstrating that mGluR5 is strongly linked to fragile X syndrome (FXS) and tuberous sclerosis (Tsc); two genetically defined disorders with significantly increased prevalence of ASD and similar core symptomatology (Krueger and Bear, 2011). Recently, we have found that single nucleotide polymorphisms (SNPs) in GRM5 (the gene encoding mGluR5) had a strong weighting in our predictive genetic classifier for ASD (Skafidas et al., 2014). MGluR5 plays a role in many critical neuronal processes, including synapse formation (Piers et al., 2012), long term depression (LTD) (Luscher and Huber, 2010), as well as regulation of astrocyte-mediated increase in excitatory post-synaptic currents (EPSCs) following activation of microglia, ATP release, and subsequent activation of the P2Y1 receptor on astrocytes (Pascual et al., 2012). In addition, it has been demonstrated that activation of mGluR5 in vitro can attenuate microglial activation as well as associated neurotoxicity following exposure to lipopolysaccharide (LPS) (Loane et al., 2009). This is of relevance to the aetiological investigation of ASD as increased microglial numbers and/or activation has been demonstrated in post-mortem investigations of the DLPFC, white matter and cerebellum in individuals with ASD (Morgan et al., 2010, Vargas et al., 2005). In addition, microglial activation in ASD has been demonstrated in vivo via positron emission tomography (PET) in the cerebellum, midbrain, pons, fusiform gyri, and the anterior cingulate and orbitofrontal cortices (Suzuki et al., 2013). These findings are interesting in light of the fact that microglia have been shown to play an important role in synaptic development and pruning, including postnatal circuits (Paolicelli et al., 2011, Schafer et al., 2012), and with a recent RNA sequencing study of post-mortem ASD brains demonstrating that a gene expression module associated with microglial activation is negatively correlated with a neuronal functioning module (Gupta et al., 2014).
Whilst mGluR5 has been implicated in ASD pathogenesis, controversy exists as to whether mGluR5 signalling is increased or decreased in the brains of individuals with ASD, with evidence for the use of drugs to potentiate or inhibit this receptor having therapeutic potential (Carlson, 2012). With respect to potentiation of mGluR5 signalling being beneficial to symptoms associated with ASD, it has been demonstrated that a positive allosteric modulator (PAM) of mGluR5, 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl) benzamide (CDPPB) corrected synaptic and biochemical defects in the hippocampus of tuberous sclerosis 2 (Tsc2+/−) mutant mice, as well as restoring cognitive deficits present in these mice (Auerbach et al., 2011). MGluR5 also has a strong interaction with N-methyl-d-aspartate (NMDA) receptors causing enhancement of NMDAR signalling (Benquet et al., 2002). This is of interest given that NMDAR hypofunction is thought to play a role in ASD, with autoantibodies to NMDA being shown to cause autistic like regression in a case study of a toddler meeting criteria for ASD diagnosis (Scott et al., 2013). ASD-like behaviours have also been exhibited in SH3 and multiple ankyrin repeat domains 3 (SHANK3) mouse models (Peca et al., 2011) with mutations and copy number variations in SHANK3 being strongly associated with ASD (Durand et al., 2007, Sykes et al., 2009) and with SHANK3 interacting directly with mGluR5 through binding of Homer and phospholipase C (PLC) to regulate signalling (Hwang et al., 2005, Tu et al., 1999). In addition, a recent meta-analysis has demonstrated that mutations in SHANK3 are present in 0.69% of patients with ASD, with SHANK1 and 2 mutations to a lesser extent present in 0.04% and 0.17% respectively (Leblond et al., 2014) with SNPs and CNVs in PLCB1 also recently been identified and linked to ASD (Girirajan et al., 2013, St Pourcain et al., 2014). Furthermore, dysregulation in the methylation status of SHANK3 in post-mortem brains of individuals with ASD versus controls has also been demonstrated (Zhu et al., 2013) as well as inhibition of SHANK3 being shown to cause a reduction in synaptic expression of mGluR5 in hippocampal and cortical neuronal cultures, leading to reduced spine density and mini EPSCs (Verpelli et al., 2011).
Activation of PLCB1 by mGluR5 has also been shown to be critical for the co-ordinated development of pre- and post-synaptic elements in mice (Hannan et al., 2001, Hannan et al., 1998, Spires et al., 2005). In addition, mGluR5 knockout (KO) mice also demonstrate hyperlocomotion and deficits in spatial working memory (Burrows et al., 2015, Gray et al., 2009, Jew et al., 2013), together with a lack of novelty-seeking behaviour (Parkitna et al., 2013) and decreased pre-pulse inhibition (Brody et al., 2004, Chen et al., 2010). These findings are of interest given that sensorimotor deficits are seen in individuals with ASD, including excessive movement (De Jong et al., 2011) together with spatial working memory deficits (Steele et al., 2007) and low novelty-seeking behaviours and reward dependence also seen in individuals with ASD (Anckarsater et al., 2006).
As GRM5 was the strongest candidate gene in our predictive genetic classifier as well as strong evidence implicating mGluR5 in ASD pathophysiology, we firstly decided to investigate whether gene expression of mGluR5 and molecules downstream of its activation are dysregulated within DLPFC of individuals with ASD versus controls together with gene expression changes in pro-inflammatory markers associated with microglial activation.. We chose to investigate the DLPFC as dysfunction or lack of normal maturation of the DLPFC is heavily implicated in ASD and is thought to underpin many ASD symptoms, including behavioural deficits (Bachevalier and Loveland, 2006), with neuroimaging studies also supporting this hypothesis (Schmitz et al., 2007, Sun et al., 2012). This part of our investigation was carried out utilising recently published microarray gene expression data patients with ASD and controls (Chow et al., 2012). We then investigated whether mGluR5 protein levels were altered in the DLPFC of individuals with ASD utilising post-mortem stereological quantitation and investigating the number of mGluR5-positive neurons and glia within the DLPFC of individuals with ASD versus normal controls. Finally, to assess the role of mGluR5 in microglial homeostasis we undertook further stereological quantitation of microglial numbers and somal size in mGluR5 KO mice.
Section snippets
Gene expression data
Microarray gene expression data were obtained from the National Centre for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) as dataset GSE28475. The authors of the original data set submitted 74 microarray files, generated from RNA extracted from DLPFC brain tissue from 57 individuals (30 ASD and 27 Controls), followed by cDNA synthesis, DASL based labelling and hybridisation to Illumina HumanRef8 v3 microarray. Full details of RNA extraction and processing can be found in the
Post-mortem DLPFC gene expression changes
Overall the age of the control group (21 ± 16 years) (mean ± SD) and ASD group (17 ± 14 years) did not differ (Mann Whitney U, p > 0.05). We log transformed the data and assessed gene expression changes for mGluR5 gene expression between groups whilst co-varying for age-related gene expression changes. MGluR5 gene expression was significantly reduced in individuals in ASD comparing levels over an age range of 2–56 years versus controls (p = 0.018) (Fig. 2A). In addition, PLCB1 (p = 0.009) (Fig. 2B) and SHANK3
Discussion
Our findings present the first combined analysis of mGluR5 gene and protein expression in the DLPFC in ASD versus controls. We demonstrate within our analysis of microarray data that gene expression of mGluR5 and specific downstream signalling proteins PLCB1 and SHANK3 were significantly reduced over all age ranges in ASD and that intensity of mGluR5-positive neurons is decreased in the DLPFC following post-mortem stereological analysis. Our gene expression and protein expression findings for
Conclusion
Findings from our post-mortem and animal model investigations point to an aetiological link existing between downregulation of mGluR5 and increased microglial density, with behaviours in the mGluR5 KO mice reflecting characteristics seen in individuals with ASD. Whilst our reported reductions in mGluR5 expression in the DLPFC in ASD may be a primary aetiological process, it may also represent a secondary alteration to NMDA dysregulation, with known functional interactions existing between these
Acknowledgments
We thank the Autism Tissue Program (ATP) for permission to utilize brain tissue from individuals with ASD and controls, with written informed consent obtained through families of donors to publish data relating to these samples. Without these consented samples this research would not be possible. Personal details of patients and their families volunteering to donate brain tissue to the ATP were kept entirely anonymous to researchers with cases de-identified prior to being sent for research
References (56)
- et al.
The impact of ADHD and autism spectrum disorders on temperament, character, and personality development
Am. J. Psychiatry
(2006) - et al.
Mutations causing syndromic autism define an axis of synaptic pathophysiology
Nature
(2011) - et al.
The orbitofrontal-amygdala circuit and self-regulation of social-emotional behavior in autism
Neurosci. Biobehav. Rev.
(2006) - et al.
NOS2 expression is restricted to neurons in the healthy brain but is triggered in microglia upon inflammation
Glia
(2014) - et al.
Two distinct signaling pathways upregulate NMDA receptor responses via two distinct metabotropic glutamate receptor subtypes
J. Neurosci.
(2002) - et al.
Effect of antipsychotic treatment on the prepulse inhibition deficit of mGluR5 knockout mice
Psychopharmacology
(2004) - et al.
Environmental enrichment ameliorates behavioral impairments modeling schizophrenia in mice lacking metabotropic glutamate receptor 5
Neuropsychopharmacology
(2015) Glutamate receptor dysfunction and drug targets across models of autism spectrum disorders
Pharmacol. Biochem. Behav.
(2012)- et al.
The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice
Psychopharmacology
(2010) - et al.
Age-dependent brain gene expression and copy number anomalies in autism suggest distinct pathological processes at young versus mature ages
PLoS Genet.
(2012)
Social deficits in IRSp53 mutant mice improved by NMDAR and mGluR5 suppression
Nat. Neurosci.
Minor neurological dysfunction in children with autism spectrum disorder
Dev. Med. Child Neurol.
Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders
Nat. Genet.
MRNA and protein expression for novel GABAA receptors theta and rho2 are altered in schizophrenia and mood disorders; relevance to FMRP-mGluR5 signaling pathway
Transl. Psychiatry
Refinement and discovery of new hotspots of copy-number variation associated with autism spectrum disorder
Am. J. Hum. Genet.
Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-d-aspartic acid receptor up-regulation
Int. J. Neuropsychopharmacol.
The efficiency of systematic sampling in stereology–reconsidered
J. Microsc.
Transcriptome analysis reveals dysregulation of innate immune response genes and neuronal activity-dependent genes in autism
Nat. Commun.
PLC-beta1, activated via mGluRs, mediates activity-dependent differentiation in cerebral cortex
Nat. Neurosci.
Phospholipase C-beta1 expression correlates with neuronal differentiation and synaptic plasticity in rat somatosensory cortex
Neuropharmacology
The interaction of phospholipase C-beta3 with Shank2 regulates mGluR-mediated calcium signal
J. Biol. Chem.
MGluR5 ablation in cortical glutamatergic neurons increases novelty-induced locomotion
PLoS ONE
Selective abolition of the NMDA component of long-term potentiation in mice lacking mGluR5
Learn. Mem.
Adjusting batch effects in microarray expression data using empirical Bayes methods
Biostatistics
Toward fulfilling the promise of molecular medicine in fragile X syndrome
Annu. Rev. Med.
Meta-analysis of SHANK Mutations in Autism Spectrum Disorders: a gradient of severity in cognitive impairments
PLoS Genet.
Activation of metabotropic glutamate receptor 5 modulates microglial reactivity and neurotoxicity by inhibiting NADPH oxidase
J. Biol. Chem.
Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co-expressed on rat and human noradrenergic terminals
Br. J. Pharmacol.
Cited by (40)
Neuroinflammation in autism spectrum disorders: Exercise as a “pharmacological” tool
2021, Neuroscience and Biobehavioral ReviewsCitation Excerpt :The middle frontal gyrus of ASD patients showed an increase TGF- β1, increased MCP-1, IL-6, and IL-10 in the anterior cingulate gyrus, and only MCP-1 was increased in CSF (Vargas et al., 2005). However, in the dorsolateral prefrontal cortex of ASD subjects, there are no changes in characteristic markers of microglial activation, such as IL-6, IL-1 β, and TNF- α (Chana et al., 2015). Elevated levels of TNF-α are associated with disrupted pineal melatonin release and sleep dysfunction in ASD (da Silveira Cruz-Machado et al., 2021).
The neuropathology of autism: A systematic review of post-mortem studies of autism and related disorders
2021, Neuroscience and Biobehavioral ReviewsCitation Excerpt :This increase in mGlur5 was also observed in the cerebellar vermis of 16 children with autism (Fatemi et al., 2011). Moreover, Chana et al. (2015) conducted a stereological investigation of the DL-PFC and found a trend to a decrease in intensity of mGluR5-positive neurons and glia, consistent with the significant reduction in mGluR5 gene expression over all age ranges in autism observed in published microarray data (Chana et al., 2015). Thus, although excitatory-inhibitory imbalance is a long proposed theory for ASD pathology, only 7 studies with a total of 64 cases and 76 controls have investigated glutamatergic impairments in post-mortem ASD brains: 4 showing higher glutamate receptor and transporter levels in the cerebellum and frontal cortex, one revealing lower KGA in the ACC, and two which found decreases in PSD-95 protein levels and genes associated with synaptic transmission in the fusiform gyrus and ACC respectively.
- 1
These authors contributed equally.